Coté GA, et al.

Sphincterotomy for Biliary Sphincter of Oddi Disorder and idiopathic Acute Recurrent Pancreatitis: THE RESPOND LONGITUDINAL COHORT

Authors: Gregory A. Coté, MD, MS¹, B. Joseph Elmunzer, MD, MSc², Haley Nitchie, MHA², Richard S. Kwon, MD³, Field F. Willingham, MD, MPH⁴, Sachin Wani, MD⁵, Vladimir Kushnir, MD⁶, Amitabh Chak, MD⁷, Vikesh Singh, MD, MSc⁸, Georgios Papachristou, MD⁹, Adam Slivka, MD, PhD¹⁰, Martin Freeman, MD¹¹, Srinivas Gaddam, MD¹², Priya Jamidar, MD¹³, Paul Tarnasky, MD¹⁴, Shyam Varadarajulu, MD¹⁵, Lydia D. Foster, MS¹⁶, and Peter B. Cotton, MD^2

Author affiliation:

Department of Medicine, Division of Gastroenterology & Hepatology, Oregon Health & Science University

² Department of Medicine, Division of Gastroenterology & Hepatology, Medical University of South Carolina, Charleston, USA

³ Department of Internal Medicine, Division of Gastroenterology & Hepatology, University of Michigan, Ann Arbor, MI

Department of Medicine, Division of Digestive Diseases, School of Medicine, Emory University, Atlanta, GA

⁵ Department of Medicine. Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

6 Department of Medicine, Division of Gastroenterology, Washington University in St. Louis School of Medicine, St. Louis, MO

Digestive Health Institute, Department of Medicine, Case Western Reserve University, Cleveland, OH

⁸ Division of Gastroenterology, Johns Hopkins Medical Institutions, Baltimore, MD

⁹ Department of Medicine, Division of Gastroenterology & Hepatology, Ohio State University, Columbus, OH

¹⁰ Department of Medicine, University of Pittsburgh, Pittsburgh, PA

¹¹ Department of Medicine, University of Minnesota, Minneapolis, MN

- ¹² Department of Medicine, Cedars Sinai School of Medicine
- ¹³ Department of Medicine, Yale University School of Medicine, New Haven, CT
- ¹⁴ Methodist Digestive Institute, Dallas, TX
- ¹⁵ Digestive Health Institute, Orlando Health, Orlando, FL

¹⁶ Department of Public Health Science, Medical University of South Carolina, Charleston, USA

Authorship:

- Gregory A Cote, MD, MS (Conceptualization: Lead; Formal analysis: Supporting; Funding acquisition: Lead; Investigation: Lead; Methodology: Lead; Writing - original draft: Lead; Writing – review & editing: Equal)
- B. Joseph Elmunzer (Investigation: Equal; Writing review & editing: Equal)
- Haley Nitchie (Project administration: Lead)
- Richard S. Kwon (Investigation: Equal; Writing review & editing: Equal)
 - Field F. Willingham (Investigation: Equal; Writing review & editing: Equal)
- 47 Sachin Wani (Investigation: Equal; Writing – review & editing: Equal)
- 48 Vladimir Kushnir (Investigation: Equal; Writing – review & editing: Equal)
- 49 Amitabh Chak (Investigation: Equal; Writing – review & editing: Equal)
- 50 51 Vikesh Singh (Investigation: Equal; Writing – review & editing: Equal)
 - Georgios Papachristou (Investigation: Equal; Writing review & editing: Equal)

Coté GA, et al.

| 52 | Adam Slivka (Investigation: Equal; Writing – review & editing: Equal) |
|---------|--|
| 53 | Shyam Varadarajulu (Investigation: Equal; Writing – review & editing: Equal) |
| 54 | Martin Freeman (Investigation: Equal; Writing – review & editing: Equal) |
| 55 | Srinivas Gaddam (Writing – review & editing: Equal) |
| 56 | Priya Jamidar (Writing – review & editing: Equal) |
| 57 | Paul Tarnasky (Investigation: Equal; Writing – review & editing: Equal) |
| 58 | Lydia D. Foster (Data curation: Lead; Formal analysis: Lead; Funding acquisition: |
| 59 | Supporting; Writing – review & editing: Equal) |
| 50 | Peter B. Cotton (Conceptualization: Supporting; Formal analysis: Supporting; Writing |
| 51 | review & editing: Equal) |
| | |

Disclosure: Research reported in this publication was supported by *the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)* of the National Institutes of Health under award number R01DK115495 (Cote, Foster, Cotton). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest disclosure: No authors have a relevant conflict of interest.

Guarantor of the article: Gregory Cote is accepting full responsibility for the conduct of the study and has had access to the data and control of the decision to publish.

Corresponding author contact information:

Gregory Cote 3181 SW Sam Jackson Park Rd Mail Code L461 Portland, OR 97239-3098 E: <u>coteg@ohsu.edu</u> F: 503-494-8776

Coté GA, et al.

| 82 83 | Acronyms | |
|----------|----------|--|
| 84 | SOD | Sphincter of Oddi disorders |
| 85 | DGBI | Disorders of gut-brain interaction |
| 86 | CBD | Common bile duct |
| 87 | iRAP | Idiopathic recurrent acute pancreatitis |
| 88 | MASLD | Metabolic dysfunction associated steatotic liver disease |
| 89 | RESPOnD | Results of Ercp for SPhincter of Oddi Disorders |
| 90 | PROM | Patient-reported outcome measures |
| 91 | SVI | Stent vs. Indomethacin trial |
| 92 | IBS | Irritable bowel syndrome |
| 93 | ULN | Upper limit of normal |
| 94 | PGIC | Patient Global Impression of Change |
| 95 | RAPID | Recurrent Abdominal Pain Intensity and Disability |
| 96 97 | EPISOD | Evaluating Predictors & Interventions in Sphincter of Oddi Dysfunction |

98 Abstract

99 Word count (limit 250): 249

Objective: Sphincter of Oddi Disorders (SOD) are contentious conditions in patients whose abdominal pain, idiopathic acute pancreatitis (iAP) might arise from pressurization at the sphincter of Oddi. The present study aimed to measure the benefit of sphincterotomy for suspected SOD.

Results: Of 316 screened, 213 were enrolled with 190 (89.2%) of these having a dilated bile duct, abnormal labs, iAP, or some combination. By imputation, an average of 122/213 (57.4% [95%CI 50.4-64.4]) improved; response rate was similar for those with complete follow-up (99/161, 61.5%, [54.0-69.0]); of these, 118 (73.3%) improved by PGIC alone. Duct size, elevated labs, and patient characteristics were not associated with response. AP occurred in 37/213 (17.4%) at a median of 6 months post-ERCP and was more likely in those with a history of AP (30.9 vs. 2.9%, p<0.0001).

Conclusion: Nearly 60% of patients undergoing ERCP for suspected SOD improve, although the contribution of a placebo response is unknown. Contrary to prevailing belief, duct size and labs are poor response predictors. AP recurrence was common and like observations from prior non-intervention cohorts, suggesting no benefit of sphincterotomy in mitigating future AP episodes.

126 Keywords: Sphincter of Oddi Dysfunction; Cholangiopancreatography, Endoscopic
 127 Retrograde; abdominal pain; acute pancreatitis; Quality of Life; Sphincterotomy

Coté GA, et al.

| Key Messages |
|--|
| WHAT IS ALREADY KNOWN ON THIS TOPIC |
| It is not clear if the sphincter of Oddi can cause abdominal pain (Functional Biliary Sphincter of Oddi Disorder) and idiopathic acute pancreatitis (Functional Pancreatic Sphincter of Oddi Disorder), and whether ERCP with sphincterotomy can ameliorate abdominal pain or pancreatitis. |
| WHAT THIS STUDY ADDS |
| Using multiple patient-reported outcome measures, most patients with suspected sphincter of Oddi disorder improve after ERCP with sphincterotomy. Duct size, elevated pancreatobiliary labs, and baseline patient characteristics are not |
| independently associated with response. |
| There is a high rate of recurrent acute pancreatitis within 12 months of sphincterotomy in those with a history of idiopathic acute pancreatitis. |
| HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY |
| Since a discrete population with a high (> 80-90%) response rate to sphincterotomy for suspected pancreatobiliary pain could not be identified, there is a need for additional observational and interventional studies that include phenotyping of patients using novel imaging or biochemical biomarkers. |
| There remains a pressing need for quantitative nociceptive biomarkers to distinguish pancreatobiliary pain from other causes of abdominal pain or central sensitization. |
| Discovery of blood-, bile-, or imaging-based biomarkers for occult microlithiasis and pancreatitis may be helpful in predicting who is likely to benefit from sphincterotomy. |
| |

Coté GA, et al.

129 Introduction

Abdominal pain is common and often associated with overlapping disorders of gutbrain interaction (DGBI). Functional sphincter of Oddi disorders (SOD) are defined by episodic abdominal pain that bear a resemblance to discomfort originating from the biliary tree, pancreas, or both,¹ but equating pain unequivocally with SOD is not possible.² Few disorders incite more controversy than SOD since there is no diagnostic test to prove that the sphincter is the source of pain and prospective studies evaluating the benefit of endoscopic sphincterotomy have been inconsistent.³⁻⁶

137 Physician-defined characteristics of SOD include the presence of a dilated common 138 bile duct (CBD), elevated liver or pancreas chemistries associated with pain,⁷ and a more 139 discrete subtype which are those idiopathic recurrent acute pancreatitis (iRAP). The latter 140 represents a diagnostic spectrum ranging from radiographic changes definitive for acute 141 pancreatitis to only pain with elevated pancreas biochemistries.⁸ In fact, experts do not 142 consider pain associated with a dilated duct and abnormal biochemistries as SOD: this has 143 been renamed papillary stenosis and sphincterotomy is recommended based on historical 144 studies.5

145 Physician-defined characteristics of SOD are not as objective as originally conceived. 146 Duct dilation is an imperfect clinical biomarker given the prevalence of physiologic dilation 147 that occurs with cholecystectomy, aging, and opioid use.⁹ Similarly, the specificity of elevated 148 liver chemistries as an SOD indicator is compromised by the high baseline rate of metabolic 149 dysfunction associated steatotic liver disease (MASLD, estimated prevalence 10-35%)¹⁰ as 150 well as abnormal aminotransferase levels in the general population (estimated prevalence 151 10-30%).¹¹⁻¹³ Finally, iRAP is a subjective diagnosis since physicians commonly diagnose 152 acute pancreatitis in the absence of radiographic changes and deeming a case idiopathic 153 varies across clinical practices and individual cases.

154

Given inconsistent outcomes and variability in current clinical practice, the Results of

Coté GA, et al.

- 155 ERCP for SPhincter of Oddi Disorders (RESPOnD) was a multicenter, prospective cohort
- 156 study designed to measure the 12-month response to sphincterotomy, as defined by patient-
- 157 reported outcome measures (PROMs), among patients undergoing ERCP for suspected
- 158 SOD.
- 159

Coté GA, et al.

160 Methods

161 Study Design, Setting, and Participants

162 RESPOnD was a prospective cohort study conducted at 14 U.S. medical centers. Eligible 163 patients included those age \geq 18 years and offered ERCP with sphincterotomy for suspected 164 SOD and no history of endoscopic sphincterotomy between January 2018 and March 2022. 165 This included all SOD subtypes: 1) Biliary: pain with a dilated bile duct, elevated liver 166 chemistries, or both, 2) Pancreatic: idiopathic acute pancreatitis, diagnosed radiographically 167 or by elevated pancreas chemistries alone, and 3) Mixed type: characteristics of both Biliary 168 and Pancreatic. For centers participating in the Stent vs. Indomethacin trial (SVI),¹⁴ patients 169 could be enrolled after their ERCP and then followed prospectively to the primary endpoint. 170 Patients with chronic pancreatitis, pregnancy, or a psychiatric disorder that precluded 171 obtaining informed consent were excluded (study protocol is available in supplemental 172 materials). A history of cholecystectomy was not required for participation if the treating 173 physician recommended ERCP as the initial intervention. Similarly, sphincter of Oddi 174 manometry was not required since most participating providers performed empiric sphincterotomies and manometry's poor reproducibility and clinical utility.¹⁵ The study was 175 176 reviewed and approved by the Human Subjects Protection Office at each participating center 177 before commencement of enrollment.

178 After signing informed consent, patients completed a baseline assessment before the 179 ERCP procedure during which they completed a series of validated questionnaires designed 180 to characterize their pain, pain-related disability, relevant medical history, and factors such as 181 underlying somatization, depression, anxiety, expectation of response, and recent opioid 182 utilization (supplementary table 1). Bile duct diameter was recorded using magnetic 183 resonance cholangiopancreatography, computed tomography, and ERCP, with dilation being 184 defined as \geq 12mm on any.⁶ A less stringent definition for bile duct dilation was considered 185 but did not impact the results significantly (data not shown). Similarly, an abnormal

Coté GA, et al.

biochemistry was defined by a liver biochemistry (AST, ALT, or alkaline phosphatase) > 2x
upper limit of normal (ULN) or > 3x ULN for pancreas chemistry (amylase or lipase).

During ERCP, the treating physician performed biliary, pancreatic, or dual sphincterotomies per their clinical judgement. Patients received periprocedural rectal indomethacin and a prophylactic pancreatic duct stent was placed per clinical judgement or per treatment allocation in the SVI trial if applicable.

Following ERCP, patients were followed quarterly in-person or by telephone for 12 months. During these visits, patients completed a series of validated, patient-reported outcome measures, queried for recent opioid and other medication use for their abdominal symptoms, hospitalizations for abdominal symptoms, and whether additional interventions were performed for their symptoms.¹⁶

- 197
- 198

Primary and secondary outcomes

199 The primary outcome definition of success was determined at 12 months and was a 200 composite of the Patient Global Impression of Change (PGIC) rated as "much improved" or 201 "very much improved", without the need for a repeat ERCP or other abdominal intervention, 202 and the same or less days of prescription opioid use during month 12 compared to the month 203 preceding the index ERCP. Secondary outcomes included the change (from baseline) in 204 pain-related disability measured by the Recurrent Abdominal Pain Intensity and Disability 205 (RAPID) instrument.¹⁷ physical and mental health summary scores as well as sub-scores 206 derived from PROMIS-29.¹⁸ Acute pancreatitis, defined by revised Atlanta criteria¹⁹, was 207 deemed non-iatrogenic unless it occurred within 30 days of the index or a follow-up ERCP.

208

209 Statistical analysis

The original sample size estimate was 360 subjects enrolled at sites participating in the SVItrial. This was based on SVI's original sample size and rate of treatment naïve subjects

Coté GA, et al.

enrolled in SVI at the time of this study's inception (33%); RESPOND enrollment began 28 months after SVI. A sample size of 360 would have resulted in a confidence interval width on our estimated proportion of success to be approximately 10±5%. Enrollment in RESPOND was lower than anticipated because of a smaller proportion of eligible subjects in SVI (24% after commencement of RESPOND) and the COVID-19 pandemic. Recruitment was terminated early due to funding expiration and analysis demonstrating a confidence interval width like our original estimate.

219 The prespecified primary analysis was an unadjusted primary outcome success 220 proportion with a two-sided 95% confidence interval. Secondary outcomes were assessed for 221 association with the primary outcome via a generalized linear model with log link and Poisson 222 distribution, with the primary outcome as the dependent variable and the secondary outcome 223 as the independent variable. Models were adjusted for the baseline value of the secondary 224 outcome. The Poisson distribution was used due to convergence issues with the prespecified 225 binomial distribution. For safety outcomes, the unadjusted proportion and two-sided 95% 226 confidence interval was estimated.

For subjects missing primary outcome data, we followed a hierarchical imputation scheme, which included multiple imputation. Multiple imputation assumed data were missing at random and a sensitivity analysis was conducted to assess the impact of missing data; multiple imputation allows for the uncertainty of missing data by creating several different plausible imputed data sets and appropriately combining results obtained from each of them.²⁰

Two multivariate logistic models associated with the imputed primary outcome were constructed. The first model considered physician-defined characteristics of SOD: elevated liver chemistry >2x ULN, bile duct diameter \ge 12mm, and history of idiopathic acute pancreatitis. The second model considered baseline patient characteristics suspected to have an association with the primary outcome by univariate testing (p \le 0.10).

Coté GA, et al.

238 Results

239 Enrollment and follow-up

During the study period, 316 patients were screened for eligibility and 216 were consented to participate. Three were excluded due to inability to complete ERCP (2) or missing informed consent documentation (1). Of the remaining 213 subjects, 179 (84.0%) were enrolled prior to their index ERCP and 34 (16.0%) after ERCP but prior to their assessment of the primary outcome *(figure 1)*. The baseline demographics of these two subgroups were similar (data not shown). A total of 169 (79.3%) completed 12-month follow-up, 36 (16.9%) were lost to follow-up, 5 (2.3%) withdrew consent, and 3 (1.4%) died.

247

248 Baseline characteristics

249 The cohort was predominantly female sex (80.8%), non-Hispanic White (82.6%), and middle 250 aged (50.6 \pm 14.9 years, **table 1**). 110/213 (51.6%) had a history of at least one episode of 251 acute pancreatitis in their lifetime. 99 (46.5%) within 12 months of their ERCP. The majority 252 had previously undergone a cholecystectomy, were nonsmokers at the time of enrollment, 253 and drank little to no alcohol. A substantial number of patients had concomitant comorbidities 254 suspected to confound their clinical presentation with abdominal pain, abnormal liver 255 chemistries, or both, including irritable bowel syndrome (41.8%), MASLD (19.7%), 256 fibromyalgia (14.1%), and gastroparesis (8.0%). Most (190/213, 89.2%) subjects presented 257 with one or more physician-defined characteristics of SOD (duct dilation, abnormal 258 pancreatobiliary biochemistries, and/or acute pancreatitis history), leaving 23 (10.8%) with 259 none of these features, suggestive of type III SOD using the Rome III definition.

The majority (143/169, 84.6%) had some degree of abdominal pain within 7 days of their index ERCP (*table 2*); the median number of pain days was 30 in the last 90, rated as a median of 7/10 and resulting in a median pain burden of 180 (interquartile range: 60, 495). Most patients characterized their pain as nociceptive (112/168, 66.7%). Approximately 1/3rd

Coté GA, et al.

| 264 | of patients had low physical or mental health, whereas nearly half of participants had a high |
|-----|---|
| 265 | likelihood of somatization. Opioids were used within 30 days of ERCP in 62/171 (36.3%). The |
| 266 | majority (90/166, 54.2%) expected their pain to be very much better or completely gone to |
| 267 | consider the procedure as successful. |
| 268 | |

269

Procedure characteristics

During ERCP, only 2/212 (0.9%) of patients underwent sphincter of Oddi manometry. However, most patients underwent a biliary sphincterotomy (204/213, 95.8%), pancreatic sphincterotomy (26/213, 12.2%), or both (20, 9.4%); 2 (0.9%) underwent a precut sphincterotomy alone and 1 (0.5%) did not have any sphincterotomy performed. A serious adverse event developed within 30 days of the index ERCP in 68/213, (31.9%); 22/213 (10.3%) developed post-ERCP pancreatitis and 1/213 (0.5%) perforation *(supplementary table 2)*.

- 277
- 278

Primary outcome: improvement following ERCP

Among 213 patients who underwent ERCP, an average of 122 (57.4% [95%CI 50.4-64.4]) met the imputed primary outcome for success at 12-month follow-up. The response rate changed minimally using the partial hierarchal imputation method: 103/179 (57.5% [50.3-64.8]). In a sensitivity analysis restricted to patients with complete follow-up data (n=161), the response rate was similar (99/161, 61.5%, [54.0-69.0]). Of those with complete follow-up data, 118 (73.3%) met the primary success by PGIC alone but 19 failed due to the need for additional procedures (n=15), new or increased need for opioids (n=3), or both (n=1).

286

287 Secondary outcome: development of acute pancreatitis > 30 days after ERCP

288 During 12-month follow-up, 37/213 (17.4%) developed at least one episode of non-iatrogenic

acute pancreatitis at a median of 6 months after the index ERCP. Non-iatrogenic acute

Coté GA, et al.

pancreatitis was more likely if the patient had a history of acute pancreatitis prior to the index
ERCP (30.9%, p<0.0001, *figure 2*), but some events occurred in those with no prior history of
acute pancreatitis (2.9%).

293

294 Relationship between physician defined SOD, patient characteristics, and outcome

295 There were no significant differences in success rates when patients were classified using 296 the physician-defined criteria for SOD, with success rates in biliary type I (51.3%), type II 297 (51.6%), type III (53.6%), pancreatic (56.1%), and mixed type (67.5%) being similar 298 (p=0.4152) (*table 3*). Similarly, a history of acute pancreatitis (60.7 vs. 53.8%, p=0.3560), an 299 elevated liver chemistry > 2x ULN (60.4 vs. 56.1%, p=0.5627), and bile duct dilation \ge 12mm 300 (56.8 vs. 57.6%, p=0.8062) did not correspond with a higher likelihood of success. Multiple 301 patient characteristics potentially associated with response to sphincterotomy were evaluated 302 by univariate analysis, with key comparisons summarized in table 4. The most significant 303 negative associations with the primary outcome were prescription opioid use in the last 30 304 days (46.8 vs. 66.3%, p=0.0236), low baseline physical health (50.0 vs. 66.2%, p=0.0512), 305 and high likelihood of somatization at the time of index ERCP (52.6 vs. 67.0%, p=0.0750). 306 There was no association between response to ERCP and a past medical history of irritable 307 bowel syndrome, MASLD, gastroparesis, smoking, and pain subtype (nociceptive or 308 neuropathic).

309

310 Multivariate analysis

311 Physician-defined characteristics of SOD were not associated with a higher likelihood of 312 response to ERCP with sphincterotomy *(table 5)*. In a regression model which considered 313 patient characteristics associated univariately ($p \le 0.10$) with response, none of these factors 314 proved to be independently associated with improvement. Recent opioid use (multivariate 315 odds ratio 0.53 [0.26 – 1.08], p=0.0810) appeared to be the most important patient factor but

Coté GA, et al.

did not remain statistically significant in the final model.

317

318 Secondary outcomes

319 Success defined using the prespecified primary outcome corresponded with change in pain-320 related disability (mean change in RAPID score from baseline, -41.2 vs. -28.6 for those who 321 failed the primary outcome, p = 0.0127). There was no association between change in RAPID 322 score and bile duct diameter in the complete case population: consistent with the analysis of 323 outcome according to Rome III SOD subtype, there was no correlation between increasing 324 bile duct diameter and reduction in RAPID score (p=0.6303, supplemental figure 1). 325 Summary physical (6.0 vs. 2.8, p = 0.0294) and mental (7.6 vs. 3.2, p=0.0140) health scores 326 improved significantly among patients meeting the study's primary outcome for success. In 327 the complete case population and except for anxiety, change in PROMIS-29 sub-scores was 328 significantly associated with the study's primary outcome (supplementary table 3). At the 329 12-month visit, the number of patients who required opioids for abdominal pain in the past 30 330 days decreased from 62/171 (36.5%) to 24/169 (14.2%).

331

332

Coté GA, et al.

334 Discussion

335

Sphincterotomy for suspected pancreatobiliary pain

336 Is SOD a fabricated etiology for abdominal pain? Many clinicians do not believe SOD is real, 337 and even fewer admit to performing ERCP to ameliorate it (at least by coding data).^{21, 22} The 338 RESPOnD cohort represents a population who share a common characteristic: their treating 339 physician interpreted their abdominal pain and other signs as concerning for SOD and 340 recommended an ERCP with sphincterotomy to address them. This is a common problem, 341 especially in the U.S. where > 1 million cholecystectomies are performed annually and a 342 growing proportion return for a first-time ERCP > 1 year postoperatively; these individuals 343 have higher rates of morbidity following these delayed ERCPs, likely because many have 344 SOD-like characteristics.²³ Clinicians have the daunting task of trying to determine the 345 etiology of a patient's abdominal pain when it is clear that pain may manifest similarly yet 346 originate from multiple organs and is often confounded by overlapping disorders of gut brain 347 interaction.^{2, 24-26} This issue of cross-sensitization imposes a substantial challenge in 348 differentiating pain originating from the pancreas, biliary tree, or another organ. A reliable 349 blood or imaging test to confirm that pain is originating in the gallbladder, sphincter of Oddi, 350 or pancreas is lacking, and RESPOnD confirms that standard pancreatobiliary chemistries 351 and duct size are inadequate prognosticators. Last, patients with abdominal pain severe or 352 sustained enough to prompt referral to RESPOnD providers are at-risk for central 353 sensitization;²⁷ this results in heightened pain signaling anywhere along the nervous system 354 and probably influences response to local interventions such as sphincterotomy. Despite 355 these challenges, most patients improved after 12 months of follow-up using RESPOnD's 356 primary outcome definition and numerous secondary outcomes derived from PROMs.

The present study attempts to address the hypothesis that SOD is a cause of abdominal pain by showing that ERCP with sphincterotomy can ameliorate these symptoms. Is the observed response rate – 57% using the pre-defined primary outcome and as high as

Coté GA, et al.

360 73% when using the PGIC alone - too high for a placebo? The placebo response is greatest 361 for patients suffering from the most severe pain and interventions (as opposed to drugs) have 362 a greater placebo effect, especially when offered as pain treatments.²⁸⁻³¹ In the "Evaluating 363 Predictors & Interventions in Sphincter of Oddi Dysfunction" (EPISOD) study which enrolled 364 patients with pain suspicious to their clinician for SOD pain but normal ducts, no pancreatitis, 365 and few with limited elevation in biochemistries, the placebo response was 37%; this might 366 have been higher using the PGIC as part of EPISOD's composite primary outcome.³ The 367 observed outcomes are similar to: 1) the placebo response in a randomized trial of a 368 protease inhibitor for painful chronic pancreatitis, and 2) the response to endoscopic therapy 369 in an open-label randomized trial compared to surgery.^{32, 33} Other factors which may increase 370 the placebo response include the patient's expectation of how much the intervention will help 371 and confidence with which the clinician explains the efficacy of their intervention.^{28, 29, 34, 35} We 372 did not measure the white coat effect, but more than half of patients expected complete or 373 near complete resolution of their symptoms. The magnitude of the intervention (ERCP and its 374 known risks) and the patient's high expectation imply a substantial placebo response. An 375 optimist could reasonably argue that a helpful placebo is still helpful... It is reassuring that 376 despite the rate of serious adverse events within 30 days of ERCP, very few patients (< 6%) 377 believed they were worse 12 months later. Another placebo-controlled randomized trial would 378 be necessary to differentiate the sphincterotomy response from the placebo response.

- 379
- 380

Physician-defined characteristics of SOD correlate poorly with response

For decades, physicians have used duct dilation and biochemistries as objective markers for impaired drainage through the sphincter of Oddi. In contrast to historic trials of SOD,^{5, 6} the present study demonstrates that physician-defined characteristics of SOD correlate poorly with response to sphincterotomy and is consistent with prior observations.³⁶ The reasons are undoubtedly multifactorial. First, the more widespread use of MRCP and endoscopic

Coté GA, et al.

386 ultrasound means RESPOnD excluded patients with choledocholithiasis who might have 387 been classified as SOD in older cohorts. Second, it is more common for gastroenterologists 388 to consult on patients with abdominal pain who are already prescribed opioids for 389 nonmalignant indications – abdominal pain or otherwise.³⁷ Opioids are a major confounder 390 since they cause bile duct dilation, elevated liver chemistries, and even acute pancreatitis; 391 44% of recent opioid users had a bile duct \geq 12 mm, as compared to 31% for those without. 392 Furthermore, recent opioids are more likely to associate with opioid-induced central 393 sensitization, disruption to the gut microbiome, and their GI side effects overlap with the 394 symptoms that mimic SOD; none of these are likely to help the chance of benefiting from 395 sphincterotomy.

- 396
- 397

The importance of pain characteristics in response

398 Nearly half of RESPOnD participants met criteria for underlying somatization at the time of 399 enrollment. This likely represents a combination of individuals with a primary functional 400 somatic syndrome and those who have developed central sensitization due to their chronic 401 abdominal pain.²⁷ Differentiating these pain subtypes is beyond the scope of this study, but 402 the finding that 72% of individuals without somatization improved is important because a 403 placebo response is unlikely to explain this completely. Similarly, patients least impacted by 404 their pain, defined by normal mental and physical health, and who did not require opioids to 405 manage their pain experienced response rates > 70%. These are populations who seem best 406 to consider offering a high-risk intervention such as ERCP.

407

408

Acute pancreatitis

409 Approximately half of RESPOnD participants presented with a history of acute pancreatitis 410 prior to their index ERCP. While a natural history group is lacking in RESPOnD, the high 411 (31%) recurrence rate of pancreatitis at a median of 6 months after ERCP suggests

Coté GA, et al.

412 sphincterotomy is ineffective in reducing the rate of acute pancreatitis in this population. The 413 observed recurrence rate is remarkably like an earlier randomized trial comparing biliary and 414 pancreatic sphincterotomy for patients with iRAP⁴ and worse than the reported recurrence 415 rate (15.1%) from a meta-analysis of 17 studies and 4,754 individuals classified as idiopathic 416 acute pancreatitis.³⁸ Having acute pancreatitis prior to the index ERCP was clearly associated 417 with a higher likelihood of developing acute pancreatitis during follow-up and even 418 comparable to patients whose pancreatitis is attributed to alcohol misuse and fail to quit.³⁹⁻⁴² 419 RESPOnD's prospective study design with scheduled research follow-up assessments might 420 have caused an inflation of the observed rate of AP when compared to studies whose 421 approach to follow-up is more passive (e.g., a measurement bias). It is also noteworthy that 422 3% of individuals with no prior history of acute pancreatitis developed an attack during the 423 first 12 months of follow-up. All of this is in addition to a significant risk of post-ERCP 424 pancreatitis (10.3%). For patients with iRAP, these data argue against a short-term benefit of 425 ameliorating subsequent pancreatitis episodes.

426

427 Limitations

428 The principal strengths of RESPOnD include its multicenter and prospective study design 429 with use of validated questionnaires to define baseline patient characteristics and PROMs. 430 Although some patients were lost to follow-up before reaching the 12-month primary 431 outcome, the success rate was similar in a sensitivity analysis restricted to patients with 432 complete follow-up data. Additionally, the success rate did not change substantially when 433 considering alternatives to the PGIC, including a reduction in pain-related disability using the 434 same definition from the EPISOD trial (RAPID score of < 6). These observations reassure 435 that the imputation method did not introduce bias and that the study's primary outcome was 436 reproducible using other PROMs. The use of neuromodulators and antispasmodics within 30 437 days of enrollment was low (49% and 28%, respectively). While this is likely due to these

Coté GA, et al.

438 agents' lack of efficacy when used earlier in their clinical course (thus prompting consultation 439 at an endoscopy referral center), the overall rate of pharmacotherapy failure at the time of 440 enrollment was not queried due to concerns about recall bias. Another limitation is the 441 heterogeneity of the patient cohort, including some patients who did not have a history of 442 cholecystectomy and a mixture of patients with biliary, pancreatic, or both subtypes of SOD. 443 Although SOD is classically defined as a post-cholecystectomy syndrome, the study team 444 elected to include these cases to maximize the study's generalizability since the decision to 445 perform ERCP was left to the discretion of the patient and treating physician based on the 446 suspicion that their abdominal pain was originating in the biliary tree, pancreas, or both. Our 447 subgroup analyses do not suggest that classically defined SOD subtypes perform differently. 448 A history of cholecystectomy was not associated with a difference in success following the 449 index ERCP (data not shown); 6 patients proceeded to cholecystectomy during follow-up, 450 and all 4 who completed follow up at 12 months reported improvement. Similarly, patients 451 with a history of acute pancreatitis as part of their SOD phenotype experienced similar 452 response rates (by PROMs) to those with classically defined biliary SOD. Last, there is a real 453 possibility of referral bias in this cohort. Patients referred to tertiary centers for suspected 454 SOD may represent those with the most severe phenotype – and thus most susceptible to 455 central sensitization and cross-sensitization. It is possible that there are unmeasured 456 confounders which influenced the response rate. Despite its multicenter design and 4 years 457 of recruitment, the final cohort was smaller than originally anticipated due to changes in 458 practice patterns at participating centers and other unmeasured factors, raising the possibility 459 of type II statistical error.

460

461 Conclusion

462 RESPOND demonstrates that nearly 60% patients who undergo ERCP for suspected SOD463 feel better after 12 months of follow-up, although the component attributable to a placebo

Coté GA, et al.

464 response is unclear. Physician-defined characteristics such as duct size, lab tests, and an 465 objective history of acute pancreatitis correlate poorly with a person's likelihood of benefiting 466 from the procedure, meaning the traditional Rome III classification system is a poor guide to 467 deciding who should be offered ERCP. Despite high technical success rates of ERCP with 468 sphincterotomy, patients with antecedent acute pancreatitis are still likely to develop a 469 recurrent attack. The most important prognostic factors for response to ERCP are determined 470 by the patient, more nuanced, and many are difficult to precisely diagnose in the clinic: those 471 without underlying somatization – a surrogate measure of disordered pain processing and/or 472 central sensitization - no recent use of opioids, and least disabled by their symptoms stand 473 the greatest odds of improvement. Those who are least desperate for intervention seem to 474 stand the best chance of improvement. RESPOnD highlights the importance of a careful 475 history, the need for more objective pain biomarkers, and additional research into the placebo 476 response of ERCP when performed for pain. In the meantime, clinicians should continue to 477 tread cautiously and avoid the temptation to offer ERCP enthusiastically when "objective" 478 features of SOD are present: they may open the door to a slippery slope.

Coté GA, et al.

480 References

500

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523 524

525

526

527

528

- 481 1. Cotton PB, Elta GH, Carter CR, et al. Rome IV. Gallbladder and Sphincter of Oddi Disorders. Gastroenterology 2016;150:1420-1429.
 483 2. Hreinsson JP, Tornblom H, Tack J, et al. Factor Analysis of the Rome IV Criteria for
- 483 2. Hreinsson JP, Tornblom H, Tack J, et al. Factor Analysis of the Rome IV Criteria for
 484 Major Disorders of Gut-Brain Interaction (DGBI) Globally and Across Geographical, Sex,
 485 and Age Groups. Gastroenterology 2023;164:1211-1222.
- 486
 487
 487
 488
 488
 Cotton PB, Durkalski V, Romagnuolo J, et al. Effect of endoscopic sphincterotomy for suspected sphincter of Oddi dysfunction on pain-related disability following cholecystectomy: the EPISOD randomized clinical trial. JAMA 2014;311:2101-9.
- 489 4. Cote GA, Imperiale TF, Schmidt SE, et al. Similar efficacies of biliary, with or without pancreatic, sphincterotomy in treatment of idiopathic recurrent acute pancreatitis. Gastroenterology 2012;143:1502-1509 e1.
- 492 5. Toouli J, Roberts-Thomson IC, Kellow J, et al. Manometry based randomised trial of 493 endoscopic sphincterotomy for sphincter of Oddi dysfunction. Gut 2000;46:98-102.
- 494 6. Geenen JE, Hogan WJ, Dodds WJ, et al. The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med 1989;320:82-7.
- 497 7. Behar J, Corazziari E, Guelrud M, et al. Functional gallbladder and sphincter of oddi disorders. Gastroenterology 2006;130:1498-509.
 499 8. Guda NM. Trikudanathan G. Freeman ML. Idiopathic recurrent acute pancreatitis.
 - 8. Guda NM, Trikudanathan G, Freeman ML. Idiopathic recurrent acute pancreatitis. Lancet Gastroenterol Hepatol 2018;3:720-728.
- 501
 502
 503
 503
 504
 10.
 Barakat MT, Banerjee S. Incidental biliary dilation in the era of the opiate epidemic: High prevalence of biliary dilation in opiate users evaluated in the Emergency Department. World J Hepatol 2020;12:1289-1298.
 504
 10.
 Fowell EE. Wong VW. Rinella M. Non-alcoholic fatty liver disease. Lancet
 - 10. Powell EE, Wong VW, Rinella M. Non-alcoholic fatty liver disease. Lancet 2021;397:2212-2224.
 - 11. Ruhl CE, Everhart JE. Upper limits of normal for alanine aminotransferase activity in the United States population. Hepatology 2012;55:447-54.
 - 12. Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003;98:960-7.
 - 13. Ioannou GN, Boyko EJ, Lee SP. The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002. Am J Gastroenterol 2006;101:76-82.
 - 14. Elmunzer BJ, Foster LD, Serrano J, et al. Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial. Lancet 2024;403:450-458.
 - 15. Suarez AL, Pauls Q, Durkalski-Mauldin V, Cotton PB. Sphincter of Oddi Manometry: Reproducibility of Measurements and Effect of Sphincterotomy in the EPISOD Study. J Neurogastroenterol Motil 2016;22:477-82.
 - 16. Cote GA, Nitchie H, Elmunzer BJ, et al. Characteristics of Patients Undergoing Endoscopic Retrograde Cholangiopancreatography for Sphincter of Oddi Disorders. Clin Gastroenterol Hepatol 2022;20:e627-e634.
 - 17. Durkalski V, Stewart W, MacDougall P, et al. Measuring episodic abdominal pain and disability in suspected sphincter of Oddi dysfunction. World J Gastroenterol 2010;16:4416-21.
 - 18. Hays RD, Spritzer KL, Schalet BD, Cella D. PROMIS((R))-29 v2.0 profile physical and mental health summary scores. Qual Life Res 2018;27:1885-1891.
 - 19. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut 2013;62:102-11.

Coté GA, et al.

- 530 20. Li P, Stuart EA, Allison DB. Multiple Imputation: A Flexible Tool for Handling Missing 531 Data. JAMA 2015;314:1966-7.
- 532 21. Smith ZL, Shah R, Elmunzer BJ, Chak A. The Next EPISOD: Trends in Utilization of 533 534 Endoscopic Sphincterotomy for Sphincter of Oddi Dysfunction from 2010-2019. Clin Gastroenterol Hepatol 2022;20:e600-e609.
- 535 22. Watson RR, Klapman J, Komanduri S, et al. Wide disparities in attitudes and practices 536 regarding Type II sphincter of Oddi dysfunction: a survey of expert U.S. endoscopists. Endosc Int Open 2016:4:E941-6.
- 537 538 539 Thiruvengadam NR, Saumoy M, Schaubel DE, et al. Rise In First-Time ERCP For 23. Benign Indications >1 Year After Cholecystectomy Is Associated With Worse Outcomes. 540 Clin Gastroenterol Hepatol 2024.
- 541 24. Doran FS. The sites to which pain is referred from the common bile-duct in man and its 542 implication for the theory of referred pain. Br J Surg 1967;54:599-606.
- 543 Kingham JG, Dawson AM. Origin of chronic right upper guadrant pain. Gut 1985;26:783-25. 544 8.
- 545 26. Chapman WP, Herrera R, Jones CM. A comparison of pain produced experimentally in 546 lower esophagus, common bile duct, and upper small intestine with pain experienced by 547 patients with diseases of biliary tract and pancreas. Surg Gynecol Obstet 1949;89:573-548 82. 549
- 27. Bourke JH, Langford RM, White PD. The common link between functional somatic 550 syndromes may be central sensitisation. J Psychosom Res 2015;78:228-36. 551 552
 - Dettori JR, Norvell DC, Chapman JR. The Art of Surgery: The Strange World of the 28. Placebo Response. Global Spine J 2019;9:680-683.
 - 29. Doherty M, Dieppe P. The "placebo" response in osteoarthritis and its implications for clinical practice. Osteoarthritis Cartilage 2009;17:1255-62.
 - 30. Gu AP, Gu CN, Ahmed AT, et al. Sham surgical procedures for pain intervention result in significant improvements in pain: systematic review and meta-analysis. J Clin Epidemiol 2017;83:18-23.
- 558 Jonas WB, Crawford C, Colloca L, et al. To what extent are surgery and invasive 31. procedures effective beyond a placebo response? A systematic review with meta-560 analysis of randomised, sham controlled trials. BMJ Open 2015;5:e009655.
 - 32. Hart PA, Osypchuk Y, Hovbakh I, et al. A Randomized Controlled Phase 2 Dose-Finding Trial to Evaluate the Efficacy and Safety of Camostat in the Treatment of Painful Chronic Pancreatitis: The TACTIC Study. Gastroenterology 2023.
 - 33. Issa Y, Kempeneers MA, Bruno MJ, et al. Effect of Early Surgery vs Endoscopy-First Approach on Pain in Patients With Chronic Pancreatitis: The ESCAPE Randomized Clinical Trial. JAMA 2020;323:237-247.
 - 34. Rossettini G, Campaci F, Bialosky J, et al. The Biology of Placebo and Nocebo Effects on Experimental and Chronic Pain: State of the Art. J Clin Med 2023;12.
 - 35. Jones MP, Guthrie-Lyons L, Sato YA, Talley NJ. Factors Associated With Placebo Treatment Response in Functional Dyspepsia Clinical Trials. Am J Gastroenterol 2023;118:685-691.
 - 36. Freeman ML, Gill M, Overby C, Cen YY. Predictors of outcomes after biliary and pancreatic sphincterotomy for sphincter of oddi dysfunction. J Clin Gastroenterol 2007;41:94-102.
 - 37. Keyes KM, Rutherford C, Hamilton A, et al. What is the prevalence of and trend in opioid use disorder in the United States from 2010 to 2019? Using multiplier approaches to estimate prevalence for an unknown population size. Drug Alcohol Depend Rep 2022;3.
 - Hajibandeh S, Jurdon R, Heaton E, et al. The risk of recurrent pancreatitis after first 38. episode of acute pancreatitis in relation to etiology and severity of disease: A systematic

553

554

555

556

557

559

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

576

577

578

Coté GA, et al.

580 review, meta-analysis and meta-regression analysis. J Gastroenterol Hepatol 581 2023;38:1718-1733.

- 39. Lankisch PG, Breuer N, Bruns A, et al. Natural history of acute pancreatitis: a long-term population-based study. Am J Gastroenterol 2009;104:2797-805; guiz 2806.
- 582 583 584 40. Yadav D, O'Connell M, Papachristou GI. Natural history following the first attack of acute 585 pancreatitis. Am J Gastroenterol 2012;107:1096-103.
- 586 41. Ahmed Ali U, Issa Y, Hagenaars JC, et al. Risk of Recurrent Pancreatitis and 587 Progression to Chronic Pancreatitis After a First Episode of Acute Pancreatitis. Clin 588 Gastroenterol Hepatol 2016;14:738-46.
- 589 42. Das R, Clarke B, Tang G, et al. Endoscopic sphincterotomy (ES) may not alter the 590 natural history of idiopathic recurrent acute pancreatitis (IRAP). Pancreatology 591 2016;16:770-7. 592

Coté GA, et al.

Figure 1. Screening and enrollment

Summary of enrollment and retention in RESPOnD. Some patients (n=37) were enrolled after their ERCP but before the 12-month primary outcome assessment. In these cases, the baseline assessment did not include completion of validated instruments characterizing their pain or psychosocial comorbidity. These subjects completed all other baseline and follow-up assessments per protocol.

Coté GA, et al.

Figure 2. Development of acute pancreatitis following ERCP for suspected SOD

Time to acute pancreatitis after the index ERCP with sphincterotomy. Episodes which occurred within 30 days of the index or follow-up ERCP are not represented.

Table 1. Patient characteristics

| Patient characteristic | Total N=213 |
|---|----------------|
| Age, Mean (SD) | 50.6 (14.9) |
| Female sex, n (%) | 172 (80.8) |
| Body mass index (kg/m ²), mean (SD) | 27.8 (6.4) |
| Ethnicity, n (%) | |
| Hispanic or Latino | 10 (4.7) |
| Not Hispanic or Latino | 203 (95.3) |
| Race, n (%) | |
| • White | 186 (87.3) |
| Black/African American | 18 (8.5) |
| Other or Multiple | 6 (3.8) |
| American Indian/Alaska Native | 1 (0.5) |
| Asian | 1 (0.5) |
| Native Hawaiian/Other Pacific Islander | 1 (0.5) |
| Smoking history, n (%) | . , |
| Never | 120 (56.3) |
| Ever | 61 (28.6) |
| Current | 32 (15.0) |
| Usual intake of alcohol during the past six months (drinks/week), n (%) | |
| • < 1 drink/week | 177 (83.1) |
| 2-6 drinks/week | 35 (16.4) |
| > 6 drinks/week | 1 (0.5) |
| Prior Cholecystectomy, n (%) | 169 (79.3) |
| Relevant past medical history, n (%) | |
| Acute pancreatitis | 110 (51.6) |
| Irritable bowel syndrome^α | 71 (41.8) |
| MASLD | 42 (19.7) |
| Fibromyalgia | 30 (14.1) |
| Gastroparesis | 17 (8.0) |
| Physician-defined characteristics of SOD, n (%) [†] | |
| Bile duct diameter ≥ 12 mm | 73/201 (36.3) |
| Pancreatic duct diameter ≥ 4 mm | 39/121 (32.2) |
| Elevated liver chemistry ≥ 2x ULN | 91/199 (45.7) |
| Elevated pancreatic chemistry ≥ 3x ULN | 49/165 (29.7) |

IBS = irritable bowel syndrome; SD = standard deviation; MASLD = metabolic dysfunction associated liver disease; ULN = upper limit of normal

 $^{\alpha}$ 170/213 (79.8%) of subjects with data available (i.e., completed the Rome IBS questionnaire) † Denominator for each biochemical and duct variable represents subjects with available data.

Table 2. Pre-procedure pain characteristics, analgesic use, and psychiatric comorbidities

| Characteristic | Denominator | |
|---|-------------|---------------|
| Pain characteristic | | |
| Response to cholecystectomy, n (%) | · | |
| Complete response | | 67/161 (41.6) |
| Partial response | 161 | 36/161 (22.4) |
| No response | | 58/161 (36.0) |
| Current pain like before cholecystectomy, n (%) | 162 | 94/162 (58.0) |
| • Days of pain episodes in past 90 days, median (IQR) (n=169) | 169 | 30 (8, 90) |
| Any abdominal pain in the last 7 days, n (%) | 169 | 143 (84.6) |
| Pain intensity (0-10) in past 90 days, median (IQR) | 168 | 7 (6, 9) |
| • Pain burden (frequency x intensity product) in past 90 days, median (IQR) | 168 | 180 (60, 495) |
| Neuropathic pain, n (%) | 167 | 32 (19.2) |
| Nociceptive pain, n (%) | 168 | 112 (66.7) |
| Psychosocial characteristic | | |
| High likelihood of depression [*] , n (%) | 167 | 21 (12.6) |
| High likelihood of anxiety^Ψ, n (%) | 167 | 35 (21.0) |
| High likelihood of somatization, n (%) | 167 | 76 (45.5) |
| Low physical health[†], n (%) | 165 | 60 (36.4) |
| Low mental health[‡], n (%) | 165 | 52 (31.5) |
| Medication use in the 30 days prior to ERCP | | |
| Opioid, n (%) | 171 | 62 (36.3) |
| • NSAIDs, n (%) | 171 | 74 (43.3) |
| Antispasmodics, n (%) | 171 | 48 (28.1) |
| Neuromodulators, n (%) | 171 | 83 (48.5) |

^{*} High likelihood of depression defined by a BSI-18 Depression T score \geq 65

^{Ψ} High likelihood of anxiety defined by BSI-18 Anxiety T score ≥ 65

[†]Low physical health defined as a PROMIS-29 Physical Health Summary T score ≤ 40

[‡] Low mental health defined as a PROMIS-29 Mental Health Summary T score ≤ 4

| | Physician-defined characteris | tic | Denominator | Success, n (%) $^{\Psi}$ | p-value | |
|-----------------------------------|--|--------------------|-------------|--------------------------|----------|--|
| | Biliany SOD alone | Both (type I) | 19 | 9.8 (51.3) | 0.4152 | |
| | Elevated liver chemistry > 2x ULN | Either (type II) | 54 | 27.9 (51.6) | | |
| SOD Subtype | Bile duct diameter ≥ 12 mm | Neither (type III) | 25 | 13.4 (53.6) | | |
| | Pancreatic SOD alone | | 59 | 33.1 (56.1) | | |
| | Mixed type [†] | 55 | 37.1 (67.5) | | | |
| Any history of acute pancreatitis | | No | 103 | 55.4 (53.8) | 0.3560 | |
| | | Yes | 110 | 66.8 (60.7) | | |
| Elevated liver chemistry > 2x ULN | | No | 108 | 60.6 (56.1) | - 0.5627 | |
| | | Yes | 91 | 55.0 (60.4) | | |
| Bile duct diameter ≥ 12mm | | No | 128 | 73.7 (57.6) | 0.8062 | |
| | | Yes | 73 | 41.5 (56.8) | | |

Table 3. Physician defined characteristics of SOD and response to ERCP treatment

SOD = Sphincter of Oddi Disorder; ULN = upper limit of normal

⁺ Patients having characteristics of biliary type I or II and pancreatic SOD (acute pancreatitis history with or without elevated pancreas chemistry > 3x ULN)

^¹ These data represent a composite of 20 imputed datasets, resulting in a reported "n" that is the average of the primary outcome.

| Patient Characteristic | | Denominator | Primary Outcome Success, n (%) | p-value | |
|---|----------------|-------------|--------------------------------|---------|--|
| Age, median (IQR) | | 213 | 48.9 (39.8 - 60) | 0.6570 | |
| Say at hith | Female | 172 | 99.3 (57.7) | 0.6725 | |
| Sex at birth | Male | 41 | 22.9 (55.9) | 0.0735 | |
| | Current Smoker | 32 | 14.6 (45.6) | | |
| Smoking history | Never Smoked | 120 | 71.3 (59.4) | 0.3516 | |
| | Past Smoker | 61 | 36.4 (59.6) | | |
| Procerintian aniaid use in last 20 days | No | 109 | 72.8 (66.7) | 0.0276 | |
| Prescription opioid use in last 30 days | Yes | 62 | 30.2 (48.7) | 0.0270 | |
| High likelihood of depression | No | 146 | 91.7 (62.8) | 0 1220 | |
| | Yes | 21 | 9.3 (44.3) | 0.1230 | |
| High likelihood of anxiety | No | 132 | 82.1 (62.2) | 0 /110 | |
| | Yes | 35 | 18.9 (53.9) | 0.4110 | |
| High likelihood of complication | No | 91 | 61 (67) | 0.0750 | |
| | Yes | 76 | 40 (52.6) | 0.0750 | |
| Low physical health | No | 105 | 69.6 (66.2) | 0.0512 | |
| | Yes | 60 | 30 (50) | 0.0312 | |
| I ow mental health | No | 113 | 72.5 (64.1) | 0 1565 | |
| | Yes | 52 | 27.1 (52.1) | 0.1505 | |
| Neuropathic pain | No | 135 | 83.4 (61.8) | 0.4080 | |
| | Yes | 32 | 17.6 (54.8) | 0.4900 | |
| Nociceptive pain | No | 56 | 35.7 (63.8) | 0.4984 | |

Table 4. Relationship between patient characteristics and response to ERCP (odds ratio)

| Patient Characteristic | Denominator | Primary Outcome Success, n (%) | p-value | | |
|--------------------------|-------------|--------------------------------|--------------|--------|--|
| | Yes | 112 | 65.3 (58.3) | | |
| Gastroparosis | No | 196 | 113.2 (57.8) | 0.0014 | |
| Gastioparesis | Yes | 17 | 9 (52.9) | 0.0014 | |
| MASID | No | 171 | 95.8 (56) | 0 4250 | |
| MAGED | Yes | 42 | 26.5 (63) | 0.4359 | |
| Irritable Bowel Syndrome | No | 99 | 64.9 (65.5) | 0 129/ | |
| | Yes | 71 | 38.1 (53.7) | 0.1304 | |

High likelihood of depression defined by BSI-18 Depression T score \geq 65; High likelihood of anxiety defined by BSI-18 Anxiety T score \geq 65; High likelihood of somatization defined by BSI-18 Somatization T score \geq 65; Low physical and mental health defined by respective PROMIS-29 Summary T score \leq 40. Statistics were calculated for each of the multiple imputed datasets and combined using SAS PROC MIANALYZE to obtain the single statistic presented in these tables.

Table 5. Factors associated with response to ERCP

| Parameter | Univariate odds ratio (95% CI) | Univariate p value | Multivariate odds ratio (95% CI) | Multivariate p value | | | |
|--|--|-----------------------|-------------------------------------|-------------------------|--|--|--|
| | Physician-defined characteristics of SOD model | | | | | | |
| Dilated bile duct ≥ 12 mm | 0.97 (0.53, 1.78) | 0.9229 | 1.18 (0.60, 2.30) | 0.6299 | | | |
| Elevated liver chemistry > 2x ULN | 1.19 (0.65, 2.19) | 0.5688 | 1.21 (0.64, 2.29) | 0.5499 | | | |
| History of acute pancreatitis | 1.33 (0.74, 2.4) | 0.3459 | 1.38 (0.71, 2.69) | 0.3428 | | | |
| Baseline patient characteristics model | | | | | | | |
| Prescription opioid use within 30 days of ERCP | 0.47 (0.24, 0.93) | 0.0304 | 0.53 (0.26, 1.08) | 0.0810 | | | |
| High likelihood of somatization | 0.54 (0.28, 1.07) | 0.0787 | 0.70 (0.33, 1.47) | 0.3432 | | | |
| Low physical health | 0.51 (0.26, 1.01) | 0.0549 | 0.64 (0.30, 1.37) | 0.2500 | | | |





Enrolled after ERCP but before primary outcome assessment @ 12 months (n=37)

Acute Pancreatitis >30 days after an ERCP

